Nektar crushed — again — as Bristol Myers ally runs into PhIII melanoma fail
Nektar could not hold up to Bristol Myers’ blockbuster Opdivo in a Phase III melanoma study, as the combo therapy went 0-for-3 on major markers …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
